The RNA helicase p68 is a potent co-activator of p53-dependent transcription in response to DNA damage. Previous independent studies have indicated that p68 and the D133p53 isoforms, which modulate the function of full-length p53, are aberrantly expressed in breast cancers. Here we identify a striking inverse association of p68 and D133p53 expression in primary breast cancers. Consistent with these findings, small interfering RNA depletion of p68 in cell lines results in a p53-dependant increase of D133p53 in response to DNA damage, suggesting that increased D133p53 expression could result from downregulation of p68 and provide a potential mechanistic explanation for our observations in breast cancer. D133p53a, which has been shown to negatively regulate the function of full-length p53, reciprocally inhibits the ability of p68 to stimulate p53-dependent transcription from the p21 promoter, suggesting that D133p53a may be competing with p68 to regulate p53 function. This hypothesis is underscored by our observations that p68 interacts with the C-terminal domain of p53, co-immunoprecipitates 133p53a from cell extracts and interacts only with p53 molecules that are able to form tetramers. These data suggest that p68, p53 and 133p53a may form part of a complex feedback mechanism to regulate the expression of D133p53, with consequent modification of p53-mediated transcription, and may modulate the function of p53 in breast and other cancers that harbour wild-type p53.
Introduction
The p53 tumour suppressor protein is a latent transcription factor that governs the expression of a network of genes that regulate cell proliferation, DNA repair, growth arrest and apoptosis (Vogelstein et al., 2000; Vousden and Lu, 2002) . Approximately 50% of all human tumours carry inactivating mutations in the p53 gene, while in cancers that have wild-type (wt) p53 (approximately 75% of all breast cancers), the function of p53 may be compromised through defects in other components of the p53 network. Breast cancer is the most common cancer in women in the western world, with an increasing incidence. Several clinical and pathological factors are important in determining the outcome of breast cancer; however, p53 function is thought to be critical, with p53 missense mutations associated with poor prognosis (Olivier et al., 2002 (Olivier et al., , 2006 Petitjean et al., 2007; Bertheau et al., 2008) .
Recently, the p53 gene was shown to express at least nine different isoforms . These arise from a combination of (a) alternative splicing in intron 2/internal translation initiation at codon 40, (b) transcription from an internal promoter in intron 4 (giving rise to D133p53 that would result in a protein missing the N-terminal 132 amino acids) and (c) alternative splicing in intron 9, which results in the production of three alternatively spliced C-terminal isoforms (a, b and g) (Courtois et al., 2002; Yin et al., 2002; Bourdon et al., 2005) . p53 isoforms are differentially expressed in a variety of cancers, including breast cancers, melanoma and squamous cell carcinomas of the head and neck Boldrup et al., 2007; Avery-Kiejda et al., 2008) . Therefore, the expression of p53 isoforms and their potential to affect the function of full-length p53 may be an important factor in determining the response to therapy and prognosis Bertheau et al., 2008) .
Certain p53 isoforms can modulate the action of full-length p53 (p53a). The D133p53a isoform inhibits p53-dependent apoptosis in mammalian cell lines , while the Zebrafish orthologue, D113p53, is inducible by full-length wt p53 and antagonizes p53-dependent apoptosis, suggesting a novel feedback pathway that can modulate the p53 response to stress (Chen et al., 2009) . The functional roles of D133p53b and D133p53g isoforms, in terms of their ability to modulate wt full-length p53 function, are still somewhat unclear, with separate studies showing conflicting results, possibly reflecting different methodologies Avery-Kiejda et al., 2008; Graupner et al., 2009) . In a recent study, D133p53a and p53b were shown to regulate p53-mediated replicative senescence with D133p53-repressing and p53b-inducing senescence (Fujita et al., 2009). p68 (Ddx5) is a growth-and developmentally regulated member (Stevenson et al., 1998) of the DEAD box family of RNA helicases that is important for a wide range of cellular processes, including pre-mRNA, rRNA and miRNA processing (Bond et al., 2001; Liu, 2002; Fukuda et al., 2007; Salzman et al., 2007) and transcription (reviewed in (Fuller-Pace, 2006; Caretti et al., 2007) . There is now a considerable body of evidence indicating that p68 is an important co-activator of transcription factors that are themselves highly regulated, for example, oestrogen receptor a (ERa) (Endoh et al., 1999; Watanabe et al., 2001) , MyoD (Caretti et al., 2006) , Runx2 (Jensen et al., 2008) , androgen receptor (AR) (Clark et al., 2008) and p53 (Bates et al., 2005) . Our previous work, and that of others, has demonstrated that p68 is aberrantly expressed/modified in several types of cancer (Causevic et al., 2001; Yang et al., 2005; Clark et al., 2008) , suggesting that p68 may be important in cancer development/progression, perhaps, in part, by regulating the activity of transcription factors such as ERa, AR or p53.
p68 interacts with, and is a potent co-activator of, p53 (Bates et al., 2005) , while p53 isoforms influence the function of full-length p53 Chen et al., 2009; Fujita et al., 2009) . Therefore, we reasoned that p68, through association with and/or modulation of expression/function of specific p53 isoforms, may have an important role in the regulation of p53 function; this idea is interesting as both p68 and the p53 isoforms are aberrantly expressed in cancers (Causevic et al., 2001; Bourdon et al., 2005; Yang et al., 2005; Boldrup et al., 2007; Avery-Kiejda et al., 2008; Clark et al., 2008) .
Here, we show that p68 expression is inversely associated with D133p53 expression in breast cancer (that is, tumours that express low levels of p68 are more likely to express D133p53 isoforms) and that p68 siRNA knockdown results in a striking increase in D133p53 expression in cell lines in response to DNA damage, consistent with the concept that p68 may repress the expression of D133p53. The increase in D133p53 on p68 knockdown is dependent on the presence of functional p53, suggesting that p68 modulates the ability of p53 to regulate D133p53 expression. Moreover, we show that D133p53 inhibits the ability of p68 to coactivate p53-dependent transcription from the p21 promoter, indicating that, whereas p68 negatively regulates D133p53 expression, D133p53 itself modulates p53 coactivation by p68. Finally, we demonstrate that p68 interacts with the C-terminal domain of p53, coimmunoprecipitates D133p53a from cell extracts and interacts only with p53 molecules that are able to form tetramers, implying that p68 may be competing with D133p53a to regulate p53 function. These findings suggest that p68, p53 and D133p53a may form part of a complex feedback mechanism to regulate the expression of D133p53 and its consequent modulation of p53-mediated transcription, and may have implications for the function of p53 in cancers that harbour wild-type p53.
Results
p68 expression is inversely associated with D133p53 expression in breast cancers To examine potential associations between p68 and p53 isoform expression in breast cancer, we examined the expression of p68 mRNA and protein, as well as p53 isoform mRNA, from a panel of 147 primary breast cancers. Considerable variation in the levels of p68 mRNA (determined by TaqMan quantitative reverse transcriptase-PCR) and protein, scored using the established 'Quick Score' method (Detre et al., 1995) ( Supplementary Figure 1) , was observed. The presence or absence of specific p53 isoform mRNAs was determined by RT-PCR using primers that distinguish between p53 molecules that contain the transactivation domain and D133p53 species, as well as between a, b and g, as previously described (Supplementary Figure 2) . Because of the p53 gene structure and the limitations of TaqMan quantitative PCR, it was not possible to obtain quantitative measurements that distinguish between the different p53 isoforms. Expression of p68 mRNA was found to be inversely associated with the expression of all D133p53 isoform mRNAs (Table 1a) . For p68 protein, there was also an inverse association between detectable p68 protein (score40) and expression of D133p53b mRNA, although the association with expression of D133p53a and D133p53g mRNA did not reach statistical significance (Table 1b) . Expression of p53 isoform protein could not be examined by immunohistochemistry because of the lack of isoform-specific antibodies.
p68 siRNA knockdown results in induction of D133p53 expression in a p53-dependent manner Given that p68 expression is inversely associated with D133p53 expression in breast cancers and D133p53 is itself a p53 target gene (Chen et al., 2009) , we considered whether p68 could regulate expression of D133p53. Whereas our previous work has demonstrated that p68 stimulates expression of p53 target genes that are normally induced by activated p53 (Bates et al., 2005) , we reasoned that, in a different transcriptional context (that is, the p53 intron 4 promoter), p68 might function to repress p53 transcriptional activity, having previously shown that p68 can, in some contexts, repress transcription (Wilson et al., 2004) . We tested whether overexpression, or siRNA knockdown, of p68 had any effect on D133p53 expression in the established breast p68 regulation of D133p53 expression/function HC Moore et al adenocarcinoma cell line model MCF-7 (wt p53) in the presence, or absence, of the DNA-damaging agent etoposide, which induces p53 activity. We found that overexpression of p68 had no effect on expression of D133p53 RNA (data not shown); however, p68 knockdown by siRNA ( Figure 1a ) resulted in a significant increase in D133p53 RNA ( Figure 1b ) in etoposidetreated cells. Similar results were obtained with a second p68 siRNA (Supplementary Figure 3) and with doxorubicin, another DNA-damaging agent (Supplementary Figure 4) . As shown previously (Bates et al., 2005) , p68 knockdown had no effect on overall p53 levels, that is, p53 species including the transactivation (TA) domain ( Figure 1c ), but resulted in a failure to induce p21 ( Figure 1d ). Western blots ( Figure 1e ) confirmed knockdown of p68, induction of p53 protein by etoposide and inhibition of p21 induction. Consistent with the observed increase in D133p53 mRNA on p68 knockdown, a longer exposure of the p53 western blot performed using the p53-specific polyclonal antibody CM-1 Fujita et al., 2009) (Figure 1e ) showed a modest increase in D133p53a protein in response to etoposide in cells treated with p68 siRNA. There was also an increase in a smaller p53 species ( Figure 1e , asterisk); however, at present, it is unclear whether this corresponds to D133p53b or D133p53g.
To determine whether the effect of p68 knockdown on D133p53 expression was p53 dependent, we tested whether D133p53 induction was also observed in HCT116 p53À/À (p53 null) cells; these cells are null for full-length p53 (Bunz et al., 1998) Similarly, there was no induction of D133p53a in HCT116 p53 þ / þ cells on simultaneous knockdown of both p68 and p53 (using an siRNA that knocks down full-length p53 and all isoforms containing the 5 0 end of the p53 gene (TAp53) but spares D133p53 species), confirming the requirement for p53 (Supplementary Figure 6) . Moreover, we did not observe any effect of p68 knockdown on D133p53 expression in T47D cells, which harbour mutant p53 (Figure 2b ), indicating that this effect is dependent on transcriptionally functional p53 and implying that p68 represses the ability of fulllength p53 to induce expression of D133p53 in response to DNA damage. This is consistent with recent reports showing that D113p53 (the Zebrafish D133p53 orthologue) is a p53 target gene and is induced by DNA damage (Chen et al., 2009; Marcel et al. 2010) . Interestingly, in our study, etoposide treatment did not significantly alter D133p53 RNA expression in untransfected MCF-7 or cells transfected with a nonspecific siRNA ( Figure 1b) ; similar results were obtained with U2OS cells (data not shown). In contrast, in HCT116 cells, etoposide treatment resulted in an increase in D133p53-RNA (Figure 2a) . However, in all cases, p68 knockdown resulted in a striking increase in D133p53 levels upon etoposide treatment, indicating that, although there seems to be some cell line dependence in the induction of D133p53-RNA by DNA damage itself, p68 knockdown in combination with DNA damage results in a marked induction of D133p53 expression in all cell lines tested.
Repression of D133p53 expression by p68 is not due to changes in transcription from the p53 intron 4 (D133p53) promoter Given that p68 can repress transcription in a promoterspecific manner (Wilson et al., 2004) and D133p53 isoforms are generated through utilization of the p68 regulation of D133p53 expression/function HC Moore et al internal promoter in intron 4 of p53 , we speculated that p68 may function to repress transcription from this promoter. As transcription from the intron 4 promoter is regulated by p53 itself (Chen et al., 2009; Marcel et al., 2010) , we generated a construct in which the p53 intron 4 promoter was fused to a luciferase reporter and measured p53-mediated transcriptional activity from this promoter, in the presence or absence of p68, by luciferase activity assays. H1299 (p53 null) cells in which p68 was knocked down by siRNA were cotransfected with a fixed amount of the intron 4-luciferase plasmid, together with increasing concentrations of a p53 expressing plasmid, and luciferase activity was measured. Cells transfected with a non-silencing siRNA were used as controls and the experiment was performed in the presence and absence of etoposide, as the increase in D133p53 mRNA upon p68 knockdown was most striking in etoposide-treated cells. As shown in Figure 3 , p68 depletion did not result in an increase in the ability of p53 to stimulate transcription from the intron 4 promoter, regardless of whether the cells were treated with etoposide. Instead, in both cases, we observed a small reduction of transcriptional activity in p68 knockdown cells, possibly as a result of pleiotropic effects of the p68 knockdown. Nevertheless, these findings suggest that the increase in D133p53 expression resulting from p68 knockdown is not due to p68 repressing transcription from the intron 4 promoter but may instead reflect effects on transcriptional elongation or RNA processing. Consistent with these findings, we did not observe any changes in recruitment of p53 to this promoter by chromatin immunoprecipitation upon p68 knockdown in MCF-7 cells (Supplementary Figure 7) , although there was a marked increase in recruitment of p53 to this promoter in response to etoposide treatment, as seen for other p53-responsive promoters.
D133p53a inhibits p68 coactivation of p53-dependent p21 induction p68 is known to stimulate p53-dependent p21 transcription (Bates et al., 2005) , whereas D133p53a has been reported to repress the expression of p21 (Fujita et al., 2009 ). These findings suggest that, in some contexts, p68 and D133p53 may have antagonistic effects on p53-dependant induction of p21 expression. To investigate this possibility, we examined the effect of p68 and D133p53a on p53-dependent transcription of a p21 promoter/luciferase reporter construct. p53 null H1299 cells were transfected with fixed amounts of plasmids expressing D133p53a and p68 and increasing amounts of a p53-expressing plasmid, together with a Renillaluciferase reporter as an internal transfection efficiency control. The experiment was performed in the absence and presence of etoposide to determine whether the effects of p68 and D133p53a are also influenced by DNA damage. p68 potently stimulated the ability of p53 to induce transcription from the p21 promoter, both in the absence and presence of etoposide (Figures 4a and b) . D133p53a exhibited a modest inhibitory effect on p53-dependent transcription from the p21 promoter in the absence of etoposide ( Figure 4a ) and had no obvious effect in the presence of etoposide (Figure 4b ). In both cases, however, D133p53a inhibited the ability of p68 to coactivate p53-dependent transcription, indicating that, at least in the context of transcription from the p21 promoter, D133p53a may be competing with p68 for regulating p53 function. Western blots were performed to confirm expression of the transfected p68, p53 and D133p53a proteins (Figures 4c and d) . Similarly, D133p53 inhibited p68 co-activation of p53-dependent transcription of endogenous p21 in H1299 cells, both in the presence and absence of etoposide (Supplementary Figure 8 ).
p68 interacts with the C-terminal domain of p53 and coimmunoprecipitates with the D133p53a isoform To explore the possible mechanisms by which p68 and D133p53a might compete to regulate p53 function, we performed a series of GST pull-down experiments to identify the regions/domains in p53 that interact with p68. We also examined which specific p53 isoforms interact with p68. As Figure 5a shows, p68 interacts with full-length p53 (p53a) and isoforms that include the C-terminal region of p53 (see Figure 5d ), but does not interact with b or g isoforms. This finding was confirmed by co-immunoprecipitation experiments between endogenous p68 and D133p53a, p53b or p53g from H1299 cell lines stably expressing these isoforms (Figure 5c ). Coimmunoprecipitation of endogenous p68 and p53a from U2OS cells served as a control (Bates et al., 2005) ; it should be noted that, in all cases, the p53-immunoprecipitating antibody was DO-12, which interacts with the DNA-binding domain and therefore immunoprecipitates all isoforms.
To further characterize the interaction between p68 and the C-terminal domain of p53, we performed GST pull-downs between p68 and several p53 mutants that harbour mutations in, or are lacking parts of, the C-terminal domain. As shown in Figure 5b , p68 does not interact with p53 species lacking the C-terminal 30 amino acids. Moreover, whereas mutations of the six C-terminal lysines, which are modified by ubiquitylation, sumoylation, acetylation and methylation (Carter and Vousden, 2009) , have no effect on interaction with p68, mutation of isoleucine 332, which has been shown to be important for p53 tetramerization (Mateu and Fersht, 1998) , abolishes interaction with p68, suggesting that p68 interacts with tetrameric p53.
Discussion
D133p53 has been shown to modulate the p53 response to DNA damage, by inhibiting p53-dependent apoptosis Chen et al., 2009 ) and p53-dependent replicative senescence (Fujita et al., 2009) , and has been implicated in invasion/metastasis of breast cancer cells (Mehta et al., 2007) . Therefore, deregulation of D133p53 expression in the 75% of breast cancers that express wt p53 (Olivier et al., 2002 (Olivier et al., , 2006 could have important implications for p53 function in tumour development and for response to chemotherapy, particularly as D133p53 itself has been reported to be a p53 target gene induced by DNA damage (Chen et al., 2009) . In this study we show that p68 expression is inversely associated with D133p53 expression in a panel of 147 breast cancers, suggesting that p68 may have a role in regulating D133p53 expression in these tumours. In this respect, our finding that depletion of p68 is associated with a striking increase in D133p53 mRNA levels in cells treated with the DNA-damaging agent etoposide suggests that p68 can repress D133p53 expression under conditions of DNA damage. Our data therefore imply that p68 may be a part of the feedback mechanism that modulates the induction of D133p53 expression after DNA damage, thus preventing inhibition of p53 function; this could be critical in tumours expressing wt p53 that are treated with chemotherapy. Moreover, given that activation of DNA damage pathways is a feature of early cancers (Halazonetis et al., 2008) , the regulation of D133p53 expression by p68 would also have important implications for tumour development. D133p53 is generated by transcription from an internal promoter in intron 4 of the p53 gene . Although in the context of other p53-responsive promoters (e.g. p21) p68 functions to co-activate p53, it was possible that p68 could function as a corepressor in the context of the intron 4 promoter; p68 has previously been shown to repress transcription from some promoters (Wilson et al., 2004) . However, our data indicate that p68 does not inhibit the ability of p53 to stimulate transcription from the intron 4 promoter in a luciferase reporter system, nor does it affect p53 recruitment to this promoter in chromatin immunoprecipitation assays in wt p53 MCF-7 cells. These observations suggest that p68 is not functioning as a transcriptional co-repressor at the level of transcription initiation, although we cannot exclude the possibility that our luciferase reporter construct is missing elements required for p68 activity. It will be interesting to determine whether p68 is instead functioning at posttranscription initiation events, possibly transcriptional elongation or RNA processing. p68 has been reported to be important for pre-mRNA splicing (Liu, 2002) and alternative splicing of certain model genes (Guil et al., 2003; Clark et al., 2008) . Our finding that the increase in D133p53 upon siRNA knockdown of p68 is dependent on p53 is particularly interesting in the light of recent reports showing that p53 has a role in transcriptional elongation (Balakrishnan and Gross, 2008) and that several RNA-binding proteins involved in posttranscriptional regulation of p53 affect p53 activity (Zhang and Chen, 2008) .
In this study we were unable to determine specifically which D133p53 RNA isoforms are induced by p68 siRNA knockdown (that is, whether D133p53a, b or g), as it was not possible to perform quantitative RT-PCR with specific primers that would distinguish between these isoforms. As new reagents become available for longerrange quantitative PCR or for the detection of each D133p53 isoform protein, it will be interesting to determine whether loss of p68 is associated with an increase in specific D133p53 isoforms. In our study, the association between p68 protein and D133p53 expression (in this case only with D133p53b) was seen at low levels of p68 protein expression in breast cancers. This would suggest that the effect is observed in the absence (or with very low levels) of p68 protein and would be consistent with our findings from the cell lines, that is, that p68-siRNA knockdown has a striking effect on D133p53 expression, whereas p68 overexpression has no effect.
Our finding that D133p53a inhibits the ability of p68 to stimulate p53-dependent transcription from the p21 Figure 5 p68 interacts with the C-terminal domain of p53 and coimmunoprecipitates with the D133p53a isoform; the ability of p53 to tetramerize is important for interaction with p68. Glutathione Stransferase-tagged (GST)-pulldowns were performed using GSTtagged p68 and (a) in vitro-translated p68 regulation of D133p53 expression/function HC Moore et al promoter raises the possibility that p68 and D133p53a may be competing for interaction with p53 or other factors at the p21 promoter. The Zebrafish homologue, 113p53a, has been shown to form heterotetramers with full-length p53 (Chen et al., 2009) , whereas our data indicate that p68 interacts with tetrameric p53. Therefore, p68 may inhibit the ability of 133p53a to form heterotetramers with full-length p53, thus favouring formation of homotetramers of full-length, functional p53. This, together with our data suggesting that p68 represses D133p53 expression and reports that D133p53 is induced by p53 (Chen et al., 2009) , implies that p68, p53 and D133p53a form part of a complex feedback mechanism to regulate the expression of D133p53 and its consequent modulation of p53 activity, as illustrated in Figure 6 . Such feedback loops are characteristic of the p53 pathway (Harris and Levine, 2005) .
In summary, our data show that p68 expression is inversely associated with expression of D133p53 in breast cancer and that p68 depletion in cells results in a striking increase in D133p53 upon DNA damage. Moreover, D133p53a seems to inhibit p68 coactivation of p53-dependent transcription from the p21 promoter, suggesting that p68 and D133p53a compete for interaction with and/or modulation of p53 function. D133p53a has been shown in several studies to inhibit p53 function and the p53 DNA damage response Chen et al., 2009; Fujita et al., 2009) ; therefore, our results support the idea that p68 may not only be important as a co-activator of full-length p53 and a regulator of the p53 DNA damage response (Bates et al., 2005) but may also be modulating p53 function at another level, namely, by regulating D133p53 expression and, consequently, its effect on p53 activity. Thus, the ability of p68 to modulate D133p53 expression could have important implications for the majority of breast cancers that harbour wt p53.
Materials and methods

Cell lines
Cell lines used in this study include wt p53 MCF-7 breast adenocarcinoma and U2OS osteosarcoma, wt p53 ( þ / þ ) and p53 null (À/À) HCT116 colon carcinoma cells, p53 mutant T47D breast ductal carcinoma and p53 null H1299 lung carcinoma cells. HCT116 cells were maintained in McCoys medium; other lines were maintained in Dulbecco's modified Eagle's medium (DMEM); all media were supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin (Invitrogen, Paisley, UK) in 5% CO 2 at 37 1C. H1299 cells stably expressing a specific p53 isoform were maintained in DMEM (as above) and 0.5 mg/ml G418 (Invitrogen).
Plasmids
For luciferase assays, plasmids expressing p68, full-length p53 and D133p53a were in pcDNA3.1( þ ) (Invitrogen). Luciferase reporter plasmids included the p21 promoter (el-Deiry et al., 1993) and the p53 intron 4 promoter (bp 11523-13076 (Genbank Accession Number X54156)) cloned in pGL3 (Promega, Madison, WI, USA). The Renilla-luciferase reporter plasmid was pRL-CMV (Promega). For GST pull-downs, plasmids expressing p53 isoforms were in pSI (Promega) and p53 deletion/mutation plasmids were in pcDNA3.1( þ ).
Antibodies
The following primary antibodies were used: p68-PAb204 (mouse monoclonal-Millipore, Temecula, CA, USA), 2907 (rabbit polyclonal) (Bates et al., 2005) ; p53-DO1 (mouse monoclonal-Santa Cruz Biotechnology), DO-12 (mouse monoclonal) and CM-1 (rabbit polyclonal) ; p21-C19 (rabbit polyclonal-Santa Cruz Biotechnology, Santa Cruz, CA, USA); actin-A2066 (rabbit polyclonal-Sigma-Aldrich, Poole, UK).
RNA extraction
Total RNA was extracted from cells using the RNeasy kit (Qiagen, Crawley, UK) and from snap-frozen breast cancer samples using the EZ1 RNA Universal Tissue Kit (Qiagen) and 1 mg of RNA was reverse-transcribed using M-MLV Reverse Transcriptase and random primers (Invitrogen).
PCR/quantitative PCR PCR to detect the presence/absence of p53 isoforms in breast cancers was performed as described previously . Quantitative PCR was performed using Applied Biosystems gene expression assays or specifically designed primer/probe sets as described in Supplementary Table 1. TATA binding protein (TBP) was used as a control and fold changes and differences between samples were calculated using the DDCt method in Microsoft Excel.
Immunohistochemistry and scoring of p68 staining in breast cancers Tissue microarrays were prepared with six 0.6-mm cores from each cancer and 4-mm sections were used for staining. Antigen Model illustrating the regulatory interactions between p68, p53 and D133p53. p53 transactivates expression of p21 and D133p53 (1). p68 alone does not influence expression of these genes but co-activates p53-dependent expression of p21 (2). p68 inhibits p53-dependent expression of D133p53 but independently of events at the intron 4 (D133p53) promoter (3). D133p53 in turn inhibits expression of p21, most likely through direct interaction with p53 and/or p68 (4). Variations in the p68 levels (as observed in tumours) will affect p21 expression not only directly but also through an indirect mechanism by regulating the levels of an inhibitor of p21 expression (ie, D133p53). Notably, D133p53 itself does not seem to influence the levels of p68 (data not shown).
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